Sava

Sava Technologies Ltd. is a London-based health technology company working to shift healthcare from a reactive to a preventative and data-driven model. Founded in 2019 by bioengineers Renato Circi and Rafaël Michali, the company emerged from their work at Imperial College London. Both founders were passionate about personal health monitoring and recognized the limited access individuals have to their own molecular health data. Their research in the lab that invented modern glucose strip technology provided them with a deep understanding of the potential and limitations of existing biosensing technologies.

The company is developing a wearable biosensor platform designed to detect and continuously monitor multiple biomarkers in the interstitial fluid just beneath the skin. This proprietary technology utilizes a multi-molecule microsensor that transmits real-time health insights to a user's smartphone. Sava's approach is designed to be minimally invasive, painless, and more affordable than many current solutions on the market. The platform's core technology consists of a smart, connected wearable patch that streamlines data delivery, making health insights effortlessly accessible.

Sava's initial product is a Continuous Glucose Monitor (CGM) aimed at the expanding diabetes management market, which is valued at over $11 billion. Unlike filament-based systems, Sava's device uses several 1mm microneedles, which aims to provide a less intimidating user experience and reduce manufacturing costs. Early results from a clinical trial with 50 patients demonstrated accurate and reliable glucose readings for up to 10 days of continuous use. The company's vision extends beyond glucose monitoring; its modular, multi-analyte architecture is designed to detect various molecules simultaneously. This opens up future applications for monitoring a wide range of conditions, tracking athletic performance, and enabling personalized therapies. The company plans to expand its sensing capabilities to include molecules like ketones, urea, proteins, and allergens.

Sava has secured a total of $32 million in funding through multiple rounds, including support from venture capital firms like Balderton Capital, Pentland Ventures, and Exor Ventures, as well as grants from the European Union and the UK Government. The capital is being used to expand the team, which now includes over 60 people, scale up manufacturing, and accelerate the regulatory approval process for its CGM. The company is targeting the $100 billion+ global wearables market, aiming to democratize access to continuous health monitoring. Keywords: biosensor, health monitoring, continuous glucose monitoring, CGM, wearable technology, preventative healthcare, personalized health, medical device, diabetes management, real-time data, molecular tracking, microsensor, interstitial fluid, multi-analyte sensing, digital health, healthtech, biomarker detection, chronic disease management, Renato Circi, Rafaël Michali